Skip to content
Predictive Biomarkers for SCLC
Radiation Induced Immune-Response in NSCLC
RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?
Role of Interleukins in TIME to Improve Immunotherapy Efficacy
Role of Radiotherapy in TIME: Good? Bad? Don’t know?
Role of SHP2 Inhibitors Alone or in Combination
ROS-1 & B-Raf Inhibitors: New Developments
Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)
Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach
Strategies to Target Minimal Residual Disease
Systemic Therapies for Mesothelioma
Targeting CEACAM5 and ROR1/ROR2 in NSCLC
The Importance of TIME in Cancer Fight: How to Target It?
The New Role of Microbiome in Lung Cancer Immunotherapy
The Role of Co-Mutations with Immunotherapy Response in NSCLC
TROP-2 and AXL as Targets in NSCLC
Updates in Bispecific Antibodies in NSCLC
What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?
What’s After PACIFIC? Can We Raise the Bar?
Update on T-Cell Lymphomas
Modern Challenges and New Options for B-cell NHL
Most Relevant News in Multiple Myeloma in 2023
The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET
Post navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok 
